Coronavirus: Update Related to the Current Outbreak of COVID-19

In December 2019, some cases of viral pneumonia were epidemiologically related to a new coronavirus in the province of Hubei, China. Subsequently, there has been an increase in infections attributable to this virus throughout China and worldwide. The World Health Organization (WHO) has officially named the infection coronavirus disease 2019 (COVID-19), and the virus has been classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This appears to be a virus from Rhinolophus bats, but the intermediate host has not yet been identified. The mechanism of infection of SARS-CoV-2 is not yet known; it appears to have affinity for cells located in the lower airways, where it replicates. The interhuman transmission of coronaviruses mainly occurs through saliva droplets and direct and indirect contact via surfaces. As of March 10, 2020, the number of cases worldwide was 113,702. Along with severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS), COVID-19 appears to cause a severe clinical picture in humans, ranging from mild malaise to death by sepsis/acute respiratory distress syndrome. The prognosis is worse in elderly patients with comorbidities. To date, there is no specific therapy for COVID-19. Prevention of SARS-CoV-2 infection implies strategies that limit the spread of the virus. WHO and other international and national bodies have developed continuously updated strategic objectives and provisions to contain the spread of the virus and infection.

[1]  M. Lal Middle East respiratory syndrome coronavirus (MERS-CoV) , 2016 .

[2]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[3]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[4]  C. Eastin,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Journal of Emergency Medicine.

[5]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[6]  Huixia Yang,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.

[7]  R. Lu,et al.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.

[8]  Charlotte Harrison,et al.  Coronavirus puts drug repurposing on the fast track , 2020, Nature Biotechnology.

[9]  Yuan Shi,et al.  Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.

[10]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[11]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[12]  T. Butler Prevention and Control , 1983 .

[13]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target , 2020, Intensive Care Medicine.

[14]  R. Wunderink,et al.  MERS, SARS and other coronaviruses as causes of pneumonia , 2017, Respirology.

[15]  G. Gao,et al.  Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses , 2016, Trends in Microbiology.

[16]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[17]  Huji Xu,et al.  The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes , 2020, bioRxiv.

[18]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[19]  D. Heymann,et al.  COVID-19: what is next for public health? , 2020, The Lancet.

[20]  News , 1992, Clinical Neurology and Neurosurgery.

[21]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[22]  D. Cleri,et al.  Severe Acute Respiratory Syndrome (SARS) , 2010, Infectious Disease Clinics of North America.

[23]  Novel Coronavirus Pneumonia Emergency Response Epidemiol Team [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[24]  China Cdc Weekly The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020 , 2020, China CDC weekly.

[25]  Xu Han-You,et al.  Acute Respiratory Syndrome (SARS) , 2004 .

[26]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[27]  Z. Memish,et al.  Reducing mortality from 2019-nCoV: host-directed therapies should be an option , 2020, The Lancet.

[28]  Jingping Yuan,et al.  Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. , 2020, JAMA.

[29]  A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia , 2020, Case Medical Research.

[30]  Silvia Angeletti,et al.  The 2019‐new coronavirus epidemic: Evidence for virus evolution , 2020, Journal of medical virology.

[31]  M. Ciccozzi,et al.  The 2019‐new coronavirus epidemic: Evidence for virus evolution , 2020, bioRxiv.

[32]  P. Hsueh,et al.  Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV , 2020, Journal of Microbiology, Immunology and Infection.